Short answer
NeuroPace Inc (NPCE) filed an 8-K current report with the SEC on July 28, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). FDA found RNS System indication expansion not approvable in current form.
NeuroPace Inc 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- FDA found RNS System indication expansion not approvable in current form
- Requested additional clinical evidence for medication-resistant IGE patients with GTC seizures
- Near-term U.S. approval and market-expansion timing delayed
- Continued FDA dialogue preserves a potential approval path, but increases evidence requirements and execution risk
Item EX-99.1 · Exhibit EX-99.1
- FDA found the IGE PMA supplement not approvable in its current form, delaying potential RNS indication expansion
- NeuroPace plans a Submission Issue Request and additional NAUTILUS clinical evidence to address FDA questions
- NAUTILUS showed 77% median GTC seizure reduction and 40% seizure freedom at 18 months
- Evaluable patients receiving stimulation for 23 of 24 months achieved 100% median GTC seizure reduction versus baseline
- 2026 management guidance excludes any contribution from expanded IGE indication
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other NeuroPace Inc 8-K filings
Get the next NPCE 8-K as it lands
Follow NPCE for push alerts, or ask the research agent what this filing means.